Skip to the main content

Medicina Fluminensis : Medicina Fluminensis, Vol. 43. No. 2., 2007.

Review article

TREATMENT OF HEPATITIS C

Davor Štimac ; Department of gastroenterology, Clinical hospital center Rijeka, Rijeka, Croatia
Jelena Luzer ; School of medicine, University of Rijeka, Croatia
Sandra Milić ; Department of gastroenterology, Clinical hospital center Rijeka, Rijeka, Croatia

Full text: croatian pdf 77 Kb

page 143-149

downloads: 1.894

cite

Abstract

SUMMARY
It is estimated that the number of hepatitis C virus (HCV) infected patients all round the world amounts to 170 million persons and it is likely to expect that the disease progression from acute to chronic ranges between 55% – 85%. The paper sets out the present knowledge on hepatitis C therapy, compares and contrasts the existing treatment methods, points at the disease side
effects and offers an insight into a future therapy trends. Nowadays, the standard HCV infection is cured by pegylated interferon and ribavirin within 24 – 48 weeks, depending on the genotype and viral response. Some special categories of patients require modified therapy. In future it is assumed that a number of new medicines, such as specific inhibitors and particularly vaccines are going to be developed thus enabling a more efficient treatment of HCV infected patients.

Keywords

hepatitis C virus (HCV); pegylated interferon; ribavirin; side effects

Hrčak ID:

22567

URI

https://hrcak.srce.hr/22567

Publication date:

25.6.2007.

Article data in other languages: croatian

Visits: 3.225 *